Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study for Metastatic Triple-Negative Breast Cancer

 Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study for Metastatic Triple-Negative Breast Cancer

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study for Metastatic Triple-Negative Breast Cancer

Shots:

  • The P-III KEYNOTE-119 study results involves assessing of Keytruda (pembrolizumab, 200mg) as monothx. vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) for the 2L/3L treatment in 622 patients in ratio (1:1) with metastatic triple-negative breast cancer
  • The P-III KEYNOTE-119 study demonstrated that it did not meet its 1EPs of OS, safety profile of Keytruda is consistent as no new safety is observed
  • Keytruda (pembrolizumab) is mAb targeting PD-1, blocking the interaction b/w PD-1 and its ligands, PD-L1 and PD-L2 thus activating T-lymphocytes affecting both tumor & healthy cells

Click here to read full press release/ article | Ref: Merck | Image: The Business Journals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post